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Abstract
Type-II L-arginine:ureahydrolase, arginase-II (Arg-II), is shown to activate mechanistic target of rapamycin complex 1
(mTORC1) pathway and contributes to cell senescence and apoptosis. In an attempt to elucidate the underlying
mechanism, we identiﬁed myosin-1b (Myo1b) as a mediator. Overexpression of Arg-II induces re-distribution of
lysosome and mTOR but not of tuberous sclerosis complex (TSC) from perinuclear area to cell periphery, dissociation
of TSC from lysosome and activation of mTORC1-ribosomal protein S6 kinase 1 (S6K1) pathway. Silencing Myo1b
prevents all these alterations induced by Arg-II. By overexpressing Myo1b or its mutant with point mutation in its
pleckstrin homology (PH) domain we further demonstrate that this effect of Myo1b is dependent on its PH domain
that is required for Myo1b-lysosome association. Notably, Arg-II promotes association of Myo1b with lysosomes. In
addition, we show that in senescent vascular smooth muscle cells with elevated endogenous Arg-II, silencing Myo1b
prevents Arg-II-mediated lysosomal positioning, dissociation of TSC from lysosome, mTORC1 activation and cell
apoptosis. Taken together, our study demonstrates that Myo1b mediates the effect of Arg-II in activating mTORC1-
S6K1 through promoting peripheral lysosomal positioning, that results in spatial separation and thus dissociation of
TSC from lysosome, leading to hyperactive mTORC1-S6K1 signaling linking to cellular senescence/apoptosis.
Introduction
The type II L-arginine:ureahydrolase arginase (Arg-II)
is expressed and can be induced in extrahepatic tissues/
cells1–3. The functions are attributed to hydrolysis of L-
arginine to urea and L-ornithine, resulting in decreased
cellular L-arginine bioavailability for vascular endothelial
nitric oxide synthase (eNOS) to generate the vasopro-
tective NO, which leads to vascular dysfunction4–6.
Moreover, recent studies demonstrate that Arg-II is
upregulated in human and murine senescent cells and
may exert enzymatic activity-independent functions, i.e.,
non-canonical effects7–9. These studies provide evidence
that Arg-II causes mitochondrial dysfunction and apop-
tosis in vascular smooth muscle cells (VSMC) and
impairs endothelial autophagy through activation of
mechanistic target of rapamycin complex 1 (mTORC1)
and ribosomal protein S6 kinase 1 (S6K1) signaling cas-
cade8,9, which plays an important role in age-associated
vascular dysfunction7–9. The underlying molecular
mechanisms of Arg-II-induced mTORC1-S6K1 activa-
tion remain unknown.
mTOR is a serine/threonine protein kinase that plays
an important role in multiple cellular functions through
two distinct complexes, i.e., mTORC1 and mTORC210.
Deregulation of mTOR signaling is linked to cellular
senescence, organism aging and a variety of human
pathologies including neurological disease, cancer, dia-
betes, and cardiovascular disease10,11. While the
mechanism of mTORC2 activation is less well char-
acterized, intensive studies have elucidated the
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mechanisms of mTORC1 activation. It has been
demonstrated that activation of mTORC1 requires
association of mTOR with lysosomes12 and dissociation
of the inhibitor tuberous sclerosis complex (TSC) from
lysosomes13,14. Association of mTOR with lysosomes is
dependent on the GTPase Rag which allows the mTOR
to be close to its activator Rheb (Ras homolog enriched
in brain) residing on lysosome surface12. Dissociation of
TSC from lysosomes can be induced by growth factors
and amino acids, resulting in relief of the inhibitory
effect of TSC on Rheb and therefore leads to activation
of mTORC1 signaling13,14. Moreover, lysosomal posi-
tioning to cell periphery has also been demonstrated to
be essential for mTORC1 activation15. However, a link
of cell peripheral lysosomal positioning to lysosome-
mTOR association and lysosome-TSC dissociation
remains unknown.
Evidence has been presented that peripheral posi-
tioning of lysosomes is regulated by molecular motor
proteins such as the plus-end-directed microtubule-
associated molecular motor kinesin superfamily pro-
teins15–18 and minus-end-directed dynein19,20. Myosin-
1b (Myo1b), an unconventional monomeric, non-
ﬁlamentous class-1 myosin is a protein with actin-
associated motor properties and widely expressed in
many cells21. It consists of an N-terminal motor domain
containing the ATP and actin-binding sites, a
calmodulin-binding neck region known as an IQ
domain, and a C-terminal tail homology domain con-
taining a pleckstrin homology (PH) domain21. PH
domain enables the direct binding of Myosin tail and
phosphatidyl inositol phosphates (PIP, PIP2)21. Myo1b
was previously shown to predominantly localize to
endosomes22 and associate with lysosomes22. However,
a role of Myo1b in lysosomal positioning and mTORC1
activation has not been investigated.
Given the important implications of mTORC1-S6K1
signaling and Arg-II in cellular (dys)functions in
numerous diseases and aging, we further elucidated the
molecular mechanisms of Arg-II-induced activation of
mTORC1-S6K1 signaling pathway. In this study, we ﬁrst
used a hepatocyte cell line lacking endogenous Arg-II
expression as a model system to study Arg-II enzymatic
activity-independent effect on mTORC1-S6K1 activation
and identiﬁed Myo1b as a novel mediator of Arg-II-
induced activation of mTORC1-S6K1 signaling. This
effect of Myo1b is attributed to its PH domain which is
required for Myo1b-lysosme association and lysosomal
positioning to cell periphery, resulting in spatial separa-
tion and thus the dissociation of TSC from lysosomes.
This molecular mechanism is further validated in the
senescent VSMCs, in which the Arg-II-Myo1b-mTORC1
axis is enhanced, contributing to vascular cell senes-
cence/apoptosis.
Results
Arg-II activates mTORC1-S6K1 and induces lysosome re-
distribution to cell periphery
In the mouse hepatocyte cell line (AML12) which does
not express endogenous Arg-II, overexpression of Arg-II
stimulated mTORC1-S6K1 signaling as monitored by
enhanced S6K1-T389 and S6-S325/326 (Fig. 1A). It is of
note that not all cells were transduced to express Arg-II
in the culture (Fig. 1B, upper panel). In cells without Arg-
II expression, lysosomes as stained with the antibody
against a lysosomal marker LAMP1 displayed perinuclear
distribution pattern, whereas in cells overexpressing Arg-
II, lysosomes were distributed more to the cell periphery
(Fig. 1B, middle panel). Confocal microscopy analysis of
the co-immunoﬂuorescence staining revealed no co-
localization of Arg-II with lysosome (Fig. 1B, bottom
panel).
Arg-II causes TSC dissociation from lysosomes without
affecting mTOR-lysosome association
We then investigated whether Arg-II affects the asso-
ciation of mTOR and/or TSC with lysosomes. Immuno-
blotting analysis demonstrated that Arg-II overexpression
signiﬁcantly decreased the lysosomal TSC2 levels and did
not affect the total cellular TSC2 (Fig. 2A). In contrast,
neither mTOR levels associated with lysosomes nor the
total cellular mTOR levels were altered by Arg-II
(Fig. 2A). The enrichment of lysosomes was conﬁrmed
by markedly increased levels of the lysosome marker
LAMP1 and markedly reduced levels of EEA1 (Early
Endosome Antigen 1, markers of early endosomes), Cal-
nexin (marker of endoplasmic reticulum membrane) and
Na+/K+-ATPase (marker of plasma membrane) in the
lysosomal fraction as compared to the total cell lysates
(Fig. 2A). Confocal immunoﬂuorescence staining revealed
that in control cells without Arg-II expression, both TSC2
(Fig. 2B) and mTOR (Fig. 2C) were associated with lyso-
somes at perinuclear area. In cells with Arg-II over-
expression, most of TSC2 did not move with lysosomes to
cell periphery and retained at perinuclear area, meaning
dissociation from lysosomes (Fig. 2B). In contrast, mTOR
remained associated with lysosomes and moved together
to cell periphery in cells expressing Arg-II (Fig. 2C). To
demonstrate that the function of lysosomal peripheral
positioning is to dissociate TSC2 from lysosomes, leading
to mTORC1 activation, HA-tagged TSC2 (HA-TSC2) was
overexpressed in the cells. HA-TSC2 displayed both
perinuclear and peripheral distribution (Fig. S1A), is able
to associate with peripheral positioned lysosomes without
affecting lysosomal peripheral positioning (Fig. S1A).
Under this condition, activation of mTORC1-S6K1 by
Arg-II was inhibited (Fig. S1B), although lysosomal per-
ipheral positioning occurred. These results suggest that
Arg-II activates mTORC1-S6K1 pathway by inducing
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Fig. 1 Arg-II induces re-distribution of lysosome to the cell periphery and activates mTORC1-S6K1 pathway. AML12 cells were transduced
with rAd/CMV as control (Con) or rAd/CMV-Arg-II (Arg-II). Two days post transduction, cells were serum-starved for 16 h and subjected to
(A) immunoblotting analysis for S6K1-T389 (p-S6K1), total S6K1, S6-S235/236 (p-S6) and total S6, as well as Arg-II and tubulin. The plot
graphs on the right show the quantiﬁcation of the signals on immunoblots; *p < 0.05; **p < 0.01 vs. Con. (B) Immunoﬂuorescence staining
of overexpressed Arg-II (green, upper panel) and lysosome marker LAMP1 (red, middle panel) in AML12 followed by counterstaining with
DAPI (blue). The merged images are shown in the bottom panel. Quantiﬁcation of percentage of cells with peripheral lysosmes was
presented as plot graphs on the right. Cells, in which more than 50% of LAMP1-positive signals localized in the peripheral region (>10 µm
from the nucleus, indicated by white dash line), are deﬁned as cells with predominantly peripheral lysosomes. **p < 0.005 vs. Con. Scale
bar = 10 µm.
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Fig. 2 (See legend on next page.)
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lysosome re-distribution to cell periphery, resulting in
spatial separation and thus dissociation of endogenous
TSC2 from lysosomes.
Arg-II activates mTORC1-S6K1 and lysosomal re-
distribution and TSC2-lysosome dissociation
independently of its enzymatic activity
To investigate whether Arg-II-induced mTORC1-S6K1
activation is dependent on its L-arginine:ureahydrolase
activity, recombinant adenoviruses (rAds) expressing
various Arg-II truncation mutants with 6His/3HA-tag
were constructed. The truncation mutants were designed
based on the strictly conserved residues identiﬁed from
multiple alignments of 31 arginase family enzymes23 (Fig.
S2A). The mutants were then expressed in the cells (Fig.
S2B). Interestingly, mutants lacking the C-terminus (i.e.,
N134, N170, N208, and N244) had no signiﬁcant effects
on mTORC1-S6K1 signaling as assessed by S6K1-T389
and S6-S235/236 levels in the cells, while the C-terminus
mutant (C110) which lacks arginase enzymatic activity
(Fig. S2), exhibited similar stimulating effect on
mTORC1-S6K1 pathway as the full length Arg-II (Fig.
S2B). The results demonstrate a non-canonical effect of
Arg-II on mTORC1-S6K1 activation through its C-
terminal domain.
Further experiments showed that the inactive N-
terminal mutant HA-N134 did not cause lysosomal per-
ipheral positioning, whereas the inactive C-terminal
mutant HA-C110 exerts the same effect as the HA-WT-
Arg-II on lysosome cell peripheral positioning and TSC2
dissociation from lysosomes (Fig. S3). This effect of HA-
N134, HA-C110, and HA-WT-Arg-II is in accordance
with their capability of activating mTORC1-S6K1 path-
way as shown in Fig. S2B.
Identiﬁcation of Myo1b as a mediator of Arg-II-induced
mTORC1-S6K1 activation
Further experiments were then carried out to identify
molecule(s) that possibly mediates the effect of Arg-II in
mTORC1-S6K1 activation. Since this effect of Arg-II is
attributable to re-distribution of lysosome to cell periph-
ery and Myo1b is a motor protein reported to be
associated with lysosome24, we examined whether Myo1b
could mediate this effect of Arg-II. For this purpose,
Myo1b was silenced by adenovirus-mediated expression
of shRNA (Fig. 3). Silencing Myo1b signiﬁcantly inhibited
the basal as well as the increased level of S6K1-T389 and
S6-S235/236 by HA-C110 and HA-WT-Arg-II (Fig. 3),
demonstrating a role of Myo1b in the non-canonical
effect of Arg-II on mTORC1-S6K1 activation. Of note
that no co-localization of Arg-II and Myo1b was observed
(Fig. S4).
Myo1b mediates lysosome re-distribution and TSC-
lysosome dissociation by Arg-II
Next we determined whether Myo1b is required for
Arg-II-induced peripheral positioning of lysosomes and
TSC dissociation from lysosomes. In cells, lysosomal
positioning to cell periphery and TSC2-lysosome dis-
sociation induced by Arg-II expression were prevented by
silencing Myo1b (Fig. 4A). Of note that silencing Myo1b
itself tended to enhance TSC2-lysosome association
under basal condition, but it did not reach statistical
signiﬁcance (Fig. 4A plot graph). In support of this
observation, immunoblotting analysis showed decreased
TSC2 levels in lysosomal fraction (but not the total TSC2)
from cells expressing Arg-II, which was prevented by
Myo1b silencing (Fig. 4B). Myo1b but not Arg-II was
detected in lysosome fraction by immunoblotting
(Fig. 4B), which supports the observation that there is no
co-localization of Arg-II with lysosome by co-
immunostaining as shown in Fig. 1B. The results
demonstrate that Myo1b mediates Arg-II-induced
mTORC1-S6K1 activation by promoting lysosomal re-
distribution to cell periphery and TSC2 dissociation from
lysosomes.
Arg-II enhances Myo1b-lysosome association through
Myo1b-PH domain leading to mTORC1-S6K1 activation
Since Myo1b was detected in lysosome fraction as
shown in Fig. 4B, we determined whether Arg-II induces
peripheral lysosome re-distribution through enhancing
Myo1b-lysosome association. Overexpression of Arg-II in
the cells enhanced Myo1b levels in lysosome fraction
(see ﬁgure on previous page)
Fig. 2 Arg-II causes dissociation of TSC from lysosome without disrupting association of mTOR with lysosomes. AML12 cells were
transduced with rAd/CMV as control (Con) or rAd/CMV-Arg-II (Arg-II). 2 days post transduction, cells were serum-starved for 16 h and subjected to (A)
immunoblotting analysis of TSC2, mTOR, LAMP1 (lysosome marker), EEA1 (marker of early endosomes), Calnexin (marker of endoplasmic reticulum
membrane) and Na+/K+-ATPase (marker of plasma membrane) in lysosome fraction and in total cell lysates. The lysosome fraction was prepared
from the total cell lysate. The graphs on the right show the quantiﬁcation of the signals on immunoblots. Data are presented as mean ± SEM. (B)
Immunoﬂuorescence staining of Arg-II (pink), LAMP1 (red), and TSC2 (green) followed by counterstaining with DAPI (blue). The merged images for
LAMP1, TSC2, and DAPI are also shown (bottom). (C) Immunoﬂuorescence staining of Arg-II (pink), LAMP1 (red), and mTOR (green) followed by
counterstaining with DAPI (blue); The merged images for LAMP1, mTOR, and DAPI are also shown (bottom). White dashes in images outline
boundaries with a predetermined distance of 10 µm from the nucleus, which deﬁnes perinuclear (inside the line) and peripheral area (outside the
line). Quantiﬁcation of co-localization of LAMP1 with TSC2 or mTOR is presented as plot graphs below. Scale bar= 10 µm. *p < 0.05 ; **p < 0.01
between the indicated groups. n.s. not signiﬁcant.
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without affecting the total Myo1b level (Fig. 5A). To
investigate whether the effect of Myo1b is dependent on
its PH domain which is believed to mediate its interaction
with lysosomes20,25,26, myc-tagged WT-Myo1b and a
mutant in its C-terminal PH domain (K966A)26 were
used. As shown in Fig. 5B, large amount of WT-Myo1b
but only tiny amount of K966A mutant were detected in
the lysosome fraction, although total expression levels of
the both were comparable. As compared to the WT-
Myo1b, the K966A mutant exhibited markedly reduced
capability of inducing lysosome peripheral positioning
(Fig. 5C) and TSC2-lysosome dissociation (Fig. S5). In
accordance, the K966 A mutant had markedly reduced
effect on activating mTORC1-S6K1 (Fig. 5D). These
results demonstrate that Arg-II induces lysosomal re-
distribution to cell periphery through enhancing associa-
tion of Myo1b with lysosomes, which is dependent on its
PH domain.
Overexpression of Arg-II activates mTORC1-S6K1 in VSMC
involving Myo1b causing VSMC apoptosis
To validate the physiological relevance of our ﬁndings
obtained from AML12 cell model system, we used human
VSMC to investigate the role of Arg-II-Myo1b-mTORC1
axis in cell senescence-associated cell apoptoisis. In young
VSMC, overexpression of Arg-II is able to activate
mTORC1-S6K1 pathway, which was prevented by silen-
cing Myo1b (Fig. 6A). In parallel, overexpression of Arg-II
in the young VSMC caused peripheral positioning of
lysosomes with concomitant TSC2 dissociation from
lysosomes, which was prevented by silencing Myo1b
(Fig. 6B). Furthermore, apoptosis induced by Arg-II
overexpression in young VSMC as assessed by Annexin-
V-FLUOS staining was signiﬁcantly reduced by Myo1b
silencing (Fig. 6C). Phase-contrast images revealed that
the cells with Myo1b silencing displayed better mor-
phology as compared with Arg-II-overexpressing cells
(Fig. 6C).
Silencing Myo1b reduces mTORC1-S6K1 and cell apoptosis
in senescent VSMC
In senescent VSMC, endogenous Arg-II is elevated with
concomitant enhanced mTORC1-S6K1 signaling as
compared to the young cells (Fig. 7A). Remarkably, the
hyperactive mTORC1-S6K1 signaling in senescent VSMC
was reduced by silencing either Arg-II or Myo1b (Fig. 7A).
The upregulated endogenous Arg-II and hyperactive
mTORC1-S6K1 were also accompanied by peripheral
lysosome positioning and TSC-lysosome dissociation,
which was prevented by silencing either Arg-II or Myo1b
in these cells (Fig. 7B). Also apoptosis in senescent VSMC
was reduced upon Myo1b silencing (Fig. 7C). These data
further support our conclusion that Arg-II-Myo1b-
mTORC1-S6K1 signaling is involved in vascular cell
senescence/apoptosis. Furthermore, immunoblotting
analysis of Myo1b in aortas reveals that protein level of
Myo1b is signiﬁcantly elevated in aortas from aging mice
as compared with those of young mice of both males and
females (Fig. S6), suggesting a potential role of Myo1b in
vascular aging. The age-associated elevation of Myo1b
levels are comparable between WT and Arg-II−/− mice
(Fig. S6).
Discussion
Our current study presents the following novel ﬁndings:
(1) Arg-II exerts a non-canonical effect on mTORC1-
Fig. 3 Myo1b mediates non-canonical effects of Arg-II on mTORC1-S6K1 activation. AML12 cells were transduced with rAd/CMV-HA-N134, HA-
C110, and HA-Arg-II in the absence or presence of rAd/U6-Myo1bshRNA. 2 days post transduction, cells were serum-starved for 16 h. Cell lysates were
then prepared and subjected to immunoblotting analysis of Myo1b, S6K1-T389 (p-S6K1), S6K1, S6-S235/236 (p-S6), and S6. The plot graphs on the
right show the quantiﬁcation of the signals on immunoblots. Data are presented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001 between the
indicated groups.
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S6K1 activation through its C-terminal domain, which is
independent of its L-arginine:ureahydrolase activity; (2)
This function of Arg-II is mediated through Myo1b by
promoting Myo1b association with lysosomes; (3) Myo1b
promotes peripheral lysosome positioning, leading to
TSC-lysosome dissociation and ultimately mTORC1-
S6K1 activation; (4) Myo1b activates mTORC1-S6K1
signaling dependently of its PH domain; (5) Finally, our
results demonstrate that Arg-II-Myo1b-mTORC1-S6K1
axis plays a role in senescence-associated VSMC
apoptosis.
Non-canonical effects of Arg-II and Myo1b in activation of
mTORC1-S6K1 signaling
Our previous study showed that Arg-II activates
mTORC1-S6K1 pathway in VSMC which does not have
eNOS expression independently of its enzymatic hydro-
lase activity8. Herein, we veriﬁed this non-canonical effect
Fig. 4 Myo1b is required for Arg-II-induced re-distribution of lysosomes and TSC dissociation from lysosomes. AML12 cells were ﬁrst
transduced either with rAd/U6-LacZshRNA as control (Con) or rAd/U6-Myo1bshRNA (Myo1b). 18 h post the ﬁrst transduction, the cells were then
transduced either with rAd/CMV as control (Con) or rAd/CMV-Arg-II (Arg-II) for overexpression. Two days post the second transduction, cells were
serum-starved for 16 h and subjected to (A) immunoﬂuorescence staining for LAMP1 (red) and TSC2 (green) followed by counterstaining with DAPI
(blue). The merged images are also shown. Scale bar= 10 µm. White dashes in images outline boundaries with a predetermined distance of 10 µm
from the nucleus, which deﬁnes perinuclear (inside the line) and peripheral area (outside the line). The plot graphs on the right presents
quantiﬁcation of LAMP1/TSC2 co-localization. (B) Immunoblotting analysis of lysosome fraction. The plot graphs on the right presents quantiﬁcation
of lysosomal TSC2/LAMP1 normalized by TSC2/LAMP1 in total cell lysates. Data are presented as mean ± SEM. *p < 0.05; **p < 0.01 between the
indicated groups.
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of Arg-II and further characterized that the C-terminal
110 amino acids (C110) fragment of Arg-II lacking any
enzymatic activity is critical for this novel function. In
contrast, several N-terminal segments are unable to
activate mTORC1-S6K1 signaling pathway. Furthermore,
we identiﬁed Myo1b as a molecule that mediates this
effect of Arg-II on mTORC1-S6K1 activation. This con-
clusion is supported by the fact that silencing Myo1b is
able to abolish the ectopic Arg-II-activated mTORC1-
S6K1 signaling. Conversely, overexpression of Myo1b in
the cells activates mTORC1-S6K1 pathway. The purpose
of using the hepatocyte cell line as a model system is that
this cell does not express endogenous Arg-II, so that the
non-canonical effect of exogenously expressed Arg-II on
mTORC1-S6K1 activation can be investigated. It is to
note that the results from this model system were veriﬁed
in human VSMCs. Similar to the hepatocyte model sys-
tem, the effects of Arg-II overexpression on TSC-
lysosome association and mTORC1-S6K1 signaling are
reproduced in young VSMCs, which is prevented by
silencing Myo1b. The cell apoptosis induced by Arg-II is
also inhibited by Myo1b silencing. Importantly, senescent
VSMCs express elevated levels of endogenous Arg-II,
display reduced TSC2-lysosome association, hyperactive
mTORC1-S6K1 signaling, and cell apoptosis. All these
senescence-associated functional changes are reduced by
silencing either Arg-II or Myo1b, validating the patho-
physiological relevance of Arg-II-Myo1b-mTORC1 axis in
promoting vascular cell aging.
Arg-II causes lysosome periphery positioning and TSC2-
lysosome dissociation via Myo1b in mTORC1-S6K1
activation
Among other mechanisms, both peripheral lysosomal
positioning and dissociation of TSC from lysosomes have
been shown to be the independent mechanisms that
regulate mTORC1-S6K1 signaling13–15,27. However, a link
between these two mechanisms has not been proposed.
Peripheral lysosomal positioning upon stimulation is
believed to bring lysosome-associated mTOR closer to its
upstream signaling molecules such as the active form of
Akt at the cell membrane15 and the peripheral lysosome
positioning is reported to be Akt-independent15. In con-
trast, dissociation of TSC from lysosome has been shown
to be dependent on Akt which phosphorylates TSC13. On
the other hand, lysosome recruitment of TSC2 is
demonstrated as an universal response to cellular stress
that inactivates mTORC1, and presence of any single
stress, such as serum starvation or amino acid removal
alone, is sufﬁcient to cause TSC2 -lysosome associated in
various cell types27. Indeed, we show that lysosomes are
predominantly positioned perinuclear and associated with
TSC2 under the condition of serum-starvation as pre-
viously reported15. Overexpression of Arg-II or Myo1b
alone is capable of promoting peripheral lysosome posi-
tioning together with mTOR but not with TSC2. This
mechanism results in spatial separation and thus dis-
sociation of TSC2 from lysosome and reliefs the inhibitory
effect of TSC2 on the mTOR activator Rheb, leading to
activation of mTORC1-S6K1 signaling. Remarkably, when
TSC2 is overexpressed, it displays both perinuclear and
peripheral distribution, which results in its association
also with peripheral lysosomes and thus overrides the
effect of Arg-II on mTORC1 activation even when per-
ipheral localization of lysosomes still occurs. These results
provide further supporting evidence that lysosome posi-
tioning to cell periphery and TSC2-lysosome dissociation,
both separately reported by previous studies13–15,27, are
causally linked as a mechanism for mTORC1 activation.
The results demonstrate that peripheral lysosome posi-
tioning causes spatial separation of TSC2 from lysosomes,
leading to their dissociation. Importantly, this mechanism
was validated in senescent VSMC in which elevated
endogenous Arg-II causes TSC2-lysosome dissociation
and accounts for hyperactive mTORC1-S6K1 signaling.
Myo1b associates with lysosome, causes lysosome
peripheral positioning, and activates mTORC1-S6K1
dependently on its PH domain
We further analyzed detailed molecular basis of Myo1b
in activation of Arg-II-mediated mTORC1-S6K1 signal-
ing. Myo1b is a widely expressed unconventional mono-
meric, non-ﬁlamentous class-1 myosin with actin-
associated motor properties21. In agreement with
(see ﬁgure on previous page)
Fig. 5 Arg-II promotes association of Myo1b with lysosomes dependently of PH domain of Myo1b, leading to lysosome peripheral
positioning. (A) Immunoblotting analysis for Myo1b levels in lysosome fraction. AML12 cells were transduced with rAd/CMV as control (Con) or rAd/
CMV-Arg-II (Arg-II). (B–D) AML12 cells were transduced with rAd/CMV as control (Con), or rAd/CMV-myc-Myo1b or the mutant rAd/CMV-myc-K966A
for overexpression. Two days post transduction, cells were serum-starved for 16 h and subjected to (B) Immunoblotting analysis of myc-Myo1b and
myc-K966A in lysosome fractions and total cell lysates using anti-myc antibody. (D) Immunoﬂuorescence staining of LAMP1 (red) and myc-Myo1b/
myc-K966A (green) followed by counterstaining with DAPI (blue). Scale bar= 10 µm. White dashes in images outline boundaries with a
predetermined distance of 10 µm from the nucleus, which deﬁnes perinuclear (inside the line) and peripheral area (outside the line). Quantiﬁcation of
cells with predominantly peripheral lysosomes is presented as plot graphs in the right panel. (D) Immunoblotting analysis of mTORC1-S6K1 signaling
and expression of myc-Myo1b and -K966A. The plot graphs on the right show the quantiﬁcation of the signals on immunoblots. Data are presented
as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001 between the indicated groups.
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previous report24, we show here that a fraction of Myo1b
also associates with lysosomes under control condition.
This association is enhanced by Arg-II, which accounts
for induction of Myo1b-mediated re-distribution of lyso-
somes to cell periphery. In support of previous reports
that lysosome contains PIP and PIP220,25 and that Myo1b
binds speciﬁcally with high afﬁnity to PI(4,5)P2 and PI
(3,4,5)P3 via its PH domain
26, we show here that a Myo1b
mutant with point mutation in PH domain (K966A) dis-
plays markedly reduced association with lysosomes and
capability to activate mTORC1-S6K1 pathway. Remark-
ably, this mutant loses the capability to induce peripheral
lysosomal positioning. These data demonstrate that
Myo1b promotes peripheral lysosomal positioning
through association with lysosomes, which is dependent
on its PH domain. This ﬁnding may stimulate the future
investigations on the proteins interacting with this
domain of Myo1b, which may lead to discovery of new
targets of inhibition of mTORC1 signaling and provide
therapeutic potential. In an effort to understand how Arg-
II promotes Myo1b triggering peripheral positioning of
lysosomes, we demonstrate that it is attributable to
enhanced association of Myo1b with lysosomes by Arg-II,
which is in line with the ﬁnding that Myo1b is associated
with lysosomes24. How Arg-II exactly enhances these
associations remains to be investigated.
To date, the well-characterized molecular motor pro-
teins involved in intracellular lysosomal positioning are
microtubule-based plus-end-directed kinesins15–18 and
minus-end directed dynein that are responsible for ante-
rograde and retrograde lysosome movement19,20, respec-
tively. Our current study provides evidence that Myo1b is
another molecular motor protein in peripheral lysosomal
positioning, contributing to mTORC1-S6K1 activation.
While Kinesin-like proteins are involved in activation of
mTORC1-S6K1 in response to growth factor and nutrient
withdrawal/replenishment, Myo1b seems mainly impli-
cated in hyperactive mTORC1-S6K1 signaling linking to
vascular aging. This conclusion is supported by the fact
that silencing Myo1b not only blunts Arg-II-mediated
peripheral lysosomal positioning, dissociation of TSC2
from lysosome and thus hyperactive mTORC1-S6K1
signaling, but also mitigates Arg-II-S6K1-mediated
apoptosis in senescent VSMCs. Moreover, a previous
study reported enhanced Myo1b mRNA level in aortas of
male aging monkey28. In current study we observed an
elevated protein level of Myo1b in aortas from aging mice
of both males and females, suggesting that Myo1b may
play a role in vascular aging. It is to note that the age-
associated elevation of Myo1b levels in mouse aortas is
not affected by Arg-II deﬁciency, suggesting that the
increase in Myo1b protein levels in aging is not regulated
by Arg-II. Taking into account that silencing Myo1b
selectively attenuates the pathological activation of
mTORC1 signaling under the conditions with elevated
Arg-II but without signiﬁcant effects on the cells under
basal condition, this selective effect of Myo1b inhibition
may provide a new avenue for the development of safer
therapies due to its less adversely effects on the normal
cells, thus, the off-target effects may be minimal. From all
the above mentioned points of view, Myo1b may be a
novel target of cardiovascular aging.
Conclusions
Our ﬁndings are summarized in a scheme that inte-
grates our view of how Arg-II activates mTORC1-S6K1
signaling implicated in vascular aging (Fig. 8). Elevated
Arg-II in aging, independently of its enzymatic activity,
enhances association of Myo1b with lysosome leading to
lysosome positioning to cell periphery, which results in
spatial separation and dissociation of TSC from lysosome
and thus relief of inhibitory effect of TSC on Rheb, and
ultimately activation of mTORC1-S6K1 signaling. This
represents another novel mechanism that regulates
mTORC1-S6K1 pathway and is implicated in vascular
aging.
Materials and methods
Materials
Reagents were purchased or obtained from the follow-
ing sources: rabbit (sc-20151) and mouse (sc-393496)
antibodies against Arg-II and mouse antibody against
Myo1b (sc-393053) were from Santa Cruz Technology Inc
(Dallas, USA); mouse antibody against S6 (#2317 s), rabbit
(see ﬁgure on previous page)
Fig. 6 Arg-II induces mTORC1-S6K1 activation in vascular smooth muscle cell (VSMC) via Myo1b. Young human umbilical vein SMCs
(HUVSMCs) were ﬁrst transduced with rAd/U6-LacZshRNA as control (Con) or rAd/U6-Myo1bshRNA, and after 18 h with rAd/CMV as control (Con) or rAd/
CMV-Arg-II (Arg-II). After 2 days of the second transduction and 16 h of serum-starvation, the cells were subjected to (A) immunoblotting analysis of
Arg-II, Myo1b and mTORC1/S6K1 signaling; (B) Immunoﬂuorescence staining for LAMP1 (red) and TSC2 (green) followed by counterstaining with
DAPI (blue). The merged images are also shown. An enlarged image of the inserts (marked with a red square) of each merged image is shown in the
bottom panel. White dashes in images outline boundaries with a predetermined distance of 7.5 µm from the nucleus, which deﬁnes perinuclear
(inside the line) and peripheral area (outside the line). Of note, HUVSMCs are smaller than AML12 cells. Scale bar= 10 µm. Quantiﬁcation of TSC2/
LAMP1 co-localization is presented in the plot graphs. (C) Detection of apoptotic cells by Annexin-V-FLUOS staining (upper panel). The lower panels
show phase-contrast images. Plot graphs on the right present quantiﬁcation of apoptotic cells. Data are presented as mean ± SEM. *p < 0.05; **p <
0.01; ***p < 0.001 between the indicated groups.
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antibodies against TSC2 (#4308 P), mTOR (#2983 s),
phospho-S6-S235/236 (#2211 s) and phospho-S6K1-T389
(#9234 s) were purchased from Cell Signaling (Danvers,
USA); mouse antibody against p70S6K (S6K1, #611260)
was from BD Transduction laboratories (New Jersey,
USA); rat antibody against LAMP1 (ab24245), rabbit
antibody against Myo1b (#194356), rabbit antibody
against EEA1 (ab2900) and against calnexin (ab22595),
monoclonal mouse antibody against alpha 1 Sodium
Potassium ATPase (Na/K-ATPase-α1) [464.6] (ab7671)
was from Abcam (Cambridge, UK); mouse antibody
against tubulin (T5168) was from Sigma (St. Louis, Mis-
souri, USA). IRDye 800-conjugated afﬁnity puriﬁed goat
anti-rabbit IgG F(c) was purchased from LI-COR Bios-
ciences (Lincoln, Nebraska USA); goat anti-mouse IgG
(H+ L) secondary antibody Alexa Fluor® 680 conjugate,
goat anti-mouse IgG (H+ L) secondary antibody Alexa
Fluor® 488 conjugate, goat anti-rabbit IgG (H+ L) sec-
ondary Antibody Alexa Fluor® 488 conjugate, goat anti-
rabbit IgG (H+ L) secondary antibody Alexa Fluor® 594
conjugate, goat anti-rat IgG (H+ L) secondary Antibody
Alexa Fluor® 488 conjugate, goat anti-rat IgG (H+ L)
secondary antibody Alexa Fluor® 546 conjugate, goat anti-
rat IgG (H+ L) secondary antibody Alexa Fluor® 680
conjugate were from Invitrogen/Thermo Fisher Scientiﬁc
(Waltham, MA USA). Insulin-transferrin-selenite sodium
and dexamethasone were from Sigma (St. Louis, Missouri,
USA). All cell culture media and materials were pur-
chased from Gibco/Thermo Fisher Scientiﬁc (Waltham,
MA USA).
Generation of expression vectors
Generation of rAd expressing various deletion mutants
of Arg-II driven by cytomegalovirus (CMV) promoter
(rAd/CMV-N134, rAd/CMV-N170, rAd/CMV-N208,
rAd/CMV-N244, rAd/CMV-C110, rAd/CMV-HA-ArgII)
(Fig. S2) was carried out with the Gateway technology
(Invitrogen Life Technologies, Carlsbad, California, USA)
according to the manufacturer’s instructions. The plasmid
pENTR11-6His-3HA-mArgII containing mouse Arg-II
cDNA with 6 ×His/3 ×HA tag at N-terminal was con-
structed in our laboratory and used as template. Each
fragment was ampliﬁed by PCR with 6 ×His/3 ×HA tag at
its N-terminal according to the primers below (the
underline indicates restriction enzyme sites): N134(1-
134aa) forward: 5′-ACGCGTCGAC ATGCACCATCAC-
CATCATCA-3′ (Sal I), reverse: 5′-AAGGAAAAAA-
GCGGCCGCCTAGCGGTGCCGGGCG-3′ (Not I); N170
(1-170aa) forward: 5′-ACGCGTCGAC ATGCACCAT-
CACCATCATCA-3′(Sal I), reverse:5′-AAGGAAAAAA-
GCGGCCGCCTATTCTTTGATGAGAAAGGA-3′ (Not
I); N208(1-208aa) forward: 5′-ACGCGTCGAC ATG-
CACCATCACCATCATCA-3′ (Sal I), reverse: 5′-AAG-
GAAAAAAGCGGCCGCCTAAATAAAATGTTCAGG-
AGG-3′ (Not I); N244(1-244aa) forward: 5′-ACGCGTC-
GAC ATGCACCATCACCATCATCA-3′ (Sal I), reverse:
5′-AAGGAAAAAAGCGGCCGCCTACCTCTGCCTTT-
TGC-3′ (Not I); C110(245-354aa) forward: 5′-AGC-
TTTGTTTAAACCCAATCCACCTGAGTTTTGATAT-
TGA-3′ (ME I), reverse: 5′-AAGGAAAAAAGCGG-
CCGCCTAAATTCTCACACATTC-3′(Not I); HA-Arg-II
(1-354aa) forward: 5′-ACGCGTCGAC ATGCACCAT-
CACCATCATCA-3′(Sal I), reverse: 5′-AAGGAAAA-
AAGCGGCCGCCTAAATTCTCACACATTC-3′ (Not I).
Generation of rAd expressing shRNA targeting mouse
and human Myo1b driven by the U6 promoter (rAd/U6-
mMyo1bshRNA and rAd/U6- hMyo1bshRNA, respectively)
was also carried out with the Gateway Technology. The
targeting sequences are indicated in boldface below (only
the sense strand is shown):
mMyo1b-shRNA:
5′- CACCGGAGCTCCTCTACAAGCTTAACGAA-
TTAAGCTTGTAGAGGAGCTCC -3′
hMyo1b-shRNA:
5′- CACCGGGCTTTATGGATCATGAAGCCGAAG-
CTTCATGATCCATAAAGCCC -3′.
The expression plasmids encoding myc-Myo1b and-
K966A were kindly provided by Lynne M. Coluccio26.
rAd/U6-LacZshRNA, rAd/U6-Arg-IIshRNA, rAd/CMV
empty vector and rAd/CMV-Arg-II were generated as
previously described7. The expression plasmid encoding
HA-TSC2 was a gift from Kunliang Guan (Addgene
plasmid # 24939, Cambridge, MA USA).
Cell culture, adenoviral transduction, and transfection
Culture of young and senescent human umbilical vein
smooth muscle cells (HUVSMC) and transduction of
HUVSMC by rAd were performed as previously
(see ﬁgure on previous page)
Fig. 7 Silencing Myo1b reduces mTORC1-S6K1 and cell apoptosis in senescent VSMC. Young (Y) and senescent (S) VSMC were transduced with
rAd/U6-LacZshRNA as control, rAd/U6-ArgIIshRNA or rAd/U6-Myo1bshRNA for silencing. After 2 days of transduction and 16 h of serum-starvation, the
cells were subjected to (A) immunoblotting analysis of Arg-II, Myo1b, and mTORC1/S6K1 signaling; (B) Immunoﬂuorescence staining for LAMP1 (red)
and TSC2 (green) followed by counterstaining with DAPI (blue). The merged images are also shown. An enlarged image of the inserts (marked with a
red square) of each merged image is shown in the bottom panel. White dashes in images outline boundaries with a predetermined distance of 7.5
µm from the nucleus, which deﬁnes perinuclear (inside the line) and peripheral area (outside the line). Scale bar= 10 µm. Quantiﬁcation of TSC2/
LAMP1 co-localization is presented in the plot graphs; (C) Detection of apoptotic cells by Annexin-V-FLUOS staining (upper panel). The lower panels
show phase-contrast images. Plot graphs on the right present quantiﬁcation of apoptotic cells. Data are presented as mean ± SEM. *p < 0.05; **p <
0.01; ***p < 0.001 between the indicated groups.
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described8,29. The alpha mouse liver 12 cell line (AML12)
was purchased from ATCC (CRL-2254). AML12 were
cultured in petri dishes coated with 1% gelatin and were
maintained in DMEM /Nutrient Mixture F-12 Ham
supplemented with 10% HIFBS, insulin-transferrin-
selenite sodium and dexamethasone as described pre-
viously30. Cells were transduced with the rAd at titers of
~200 multiplicities of infection and then cultured in
complete medium for 2 days and then switched to serum-
free medium overnight before experiments. Transfection
of the cells was performed using Lipofectmine 3000
Transfection Reagent (L3000008, Invitrogen/ Thermo
Fisher Scientiﬁc) (Waltham, MA USA) according to
manufacturer’s instructions.
Animals
Arg-II−/− mice were kindly provided by Dr. William
O’Brien31 and backcrossed to C57BL/6 J for more than
eight generations. Wild type (WT) and Arg-II−/− off-
spring (F2) from hetero/hetero (F1) cross were interbred
to obtain WT and Arg-II−/− mice (F3), respectively, for
our experiments. The mice were maintained in conven-
tional conditions: 23 °C, 12-h light-dark cycle and fed a
normal chow and had free access to tap water. Young
(5–7 months) and old (22–24 months) mice were sacri-
ﬁced as previously described32. Aortas was isolated and
snap-frozen in liquid nitrogen and kept at −80 °C until
processed. Animal work was approved by the Ethical
Committee of Veterinary Ofﬁce of Fribourg (Nr.
2013_08_FR), Switzerland and was performed in com-
pliance with guidelines on animal experimentation at our
institution.
Immunoblotting
Cell and aorta lysate preparation, sodium dodecyl sul-
fate polyacrylamide gel electrophoresis, transfer of sodium
dodecyl sulfate gels to an Immobilon-P membranes
(Millipore) were performed as previously described7. The
resultant membrane was ﬁrst incubated with the corre-
sponding primary antibody at 4 °C overnight with gentle
agitation after blocking with 5% skimmed milk. The blot
was then further incubated with a corresponding anti-
mouse (Alexa ﬂuor 680 conjugated) or anti-rabbit (IRDye
800 conjugated) or anti-rat (Alexa ﬂuor 680 conjugated)
secondary antibody. Signals were visualized using Odyssey
Infrared Imaging System (LI-COR Biosciences, Lincoln,
Nebraska USA). Quantiﬁcation of the signals was per-
formed using NIH Image 1.62 software (U. S. National
Institutes of Health).
Immunoﬂuorescence staining
Cells grown on glass coverslips were ﬁxed with 4%
paraformaldehyde, permeabilized with 0.2% Triton X-100,
and blocked with 1% BSA in PBS. Coverslips were
Fig. 8 Schematic summary of the major ﬁndings of the current study. Arg-II promotes association of Myo1b with lysosomes, which causes
peripheral lysosomal positioning, resulting in spatial separation and thus dissociation of TSC from lysosomes. The relief of inhibitory effect of TSC on
mTOR upstream activator Rheb ultimately leads to the activation of mTORC1-S6K1 signaling, contributing to vascular cell senescence phenotype, i.e.,
cell apoptosis, impaired autophagy, and mitochondrial dysfunction
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incubated with primary antibody overnight at 4 °C, fol-
lowed by incubation with Alexa Fluor-labeled secondary
antibodies for 1 h at room temperature, and mounted.
Images were acquired through 63 × objectives with Leica
TCS SP5 confocal laser microscope. All of the confocal
images shown in the current study correspond to repre-
sentative images of one confocal section throughout the
focal plane of the nucleus of one cell taken at the same
exposure and magniﬁcation.
Quantiﬁcation of lysosomal distribution
Quantiﬁcation of lysosomal distribution was performed
according to the description with modiﬁcation from Kor-
olchuk et al15. In brief, cells were categorized into
perinuclear-dominant lysosomal distribution (more than
50% of LAMP1-positive signals localized in the perinuclear
region, < 10 µm (AML12 cells) or 7.5 µm (HUVSMCs)
from the nucleus) and peripheral-dominant distribution
(more than 50% of LAMP1-positive signals localized in the
peripheral region, >10 µm (AML12 cells) or 7.5 µm
(HUVSMCs) from the nucleus). Of note, HUVSMCs are
smaller than AML12 cells. Quantiﬁcation is based on at
least three independent experiments, each carried out in
duplicate, and around 150 cells with only one nucleus were
counted in each slide; the quantiﬁcation was blinded cal-
culated. The data are presented as proportion of cells with
predominantly (>50%) peripheral lysosomes.
Quantiﬁcation of TSC2/lysosome co-localization
Co-localization of TSC2/lysosome in confocal micro-
scopy experiments was quantiﬁed using the Coloc2 plugin
of Fiji software based on at least three independent
experiments. The Pearson’s co-localization coefﬁcient of
TSC2/LAMP1 (with threshold) was used to quantify the
co-localization of TSC2 and lysosomes. For each condi-
tion, 20–30 cells were examined.
Lysosome isolation
The Lysosomes of transduced AML12 cells were iso-
lated according to the protocol of Lysosome Enrichment
Kit for Tissues and Cultured Cells (Invitrogen, # 89839).
Detection of apoptotic cells
Apoptosis of transduced HUVSMCs was detected with
Annexin-V-FLUOS Staining Kit (Roche Applied Science
#1988549, Basel, Switzerland) according to the manu-
facturer’s instructions. Quantiﬁcation was presented by
the ratio of apoptotic cells/total cells.
Statistics
The Kolmogorov–Smirnov test was used to ﬁrst deter-
mine whether the data deviate from Gaussian distribu-
tions. For normal distributed values, statistical analysis
was performed with the Student’s t-test for unpaired
observations or analysis of variance with Bonferroni’s
post-test, and data are given as means ± SEM. For non-
normal distributed values, non-parametric statistical
analysis was performed with the Kruskal–Wallis test with
a Dunn’s multiple comparison post-test, and data are
expressed as medians with interquartile range. p ≤ 0.05 is
considered to indicate a statistical difference. The n
indicates the number of individual animals used or of
individual experiments when conducted with cells.
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